Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity.

@article{Ibrahim2009AngiotensinconvertingEI,
  title={Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity.},
  author={Mohamed Abdellah Ibrahim and Osama M. Ashour and Yasmin F Ibrahim and Hussian I El-Bitar and Wafaey Mohammad Gomaa and Salama R Abdel-Rahim},
  journal={Pharmacological research},
  year={2009},
  volume={60 5},
  pages={
          373-81
        }
}
Doxorubicin (Dox) is a potent anticancer agent; its clinical use is limited for its marked cardiotoxicity and nephrotoxicity. The present study investigated the possible protective effect of telmisartan, an angiotensin AT(1)-receptor blocker versus captopril, an angiotensin-converting enzyme inhibitor, on Dox-induced cardiotoxicity and nephrotoxicity in rats. Rats were allocated into four groups. Control group, Dox group, Dox+telmisartan group, and Dox+captopril group. Cardiotoxicity and… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 39 CITATIONS

Similar Papers

Loading similar papers…